Meanwhile, this meta-analysis suggests that postoperative detection with CD34- and/or CD31- of VM+ tumor samples in MM would be useful in finding critical therapy targets as well as for making better follow-up plans. The gene discussed is CD34; the disease is Miyoshi myopathy.